ENDOSCOPY SOLUTIONS PERFORMANCE
Last year’s comparative figures are stated in brackets.
Endoscopy Solutions sales for the quarter were up,
reflecting organic growth of 22.3% (10.6%) and report-
ed growth of 21.7% (12.8%), with revenue of DKK
807m (DKK 663m). Endoscopy Solutions accounted
for 59% (56%) of Ambu’s total revenue in Q2 2023/24.
Feedback continues to be positive, resounding the
aScope™ 5 Broncho’s excellent performance, com-
pared to reusable bronchoscopes.
Large and aScope™ Duodeno. The aScope™ Gastro
Large is designed to address acute therapeutic
procedures in the ICU, thereby complimenting the
aScope™ Gastro solution, which targets procedures
outside of the endoscopy unit, such as surgical
gastroscopies in the OR and bedside procedures in
the ICU. Both solutions are now commercially available
in Europe and North America. Globally, the aScope™
Gastro Large targets 1.5 million annual procedures,
while the aScope™ Gastro is expected to meet needs
within a market of 2 million annual procedures.
In Q2, Ambu is also announcing Ambu Broncho
Simulator, which is a software-based training platform
developed with Artificial Intelligence, intended for
pulmonology training.
The satisfactory growth in Endoscopy Solutions was
mainly driven by Ambu’s pre-existing solutions in the
growing single-use market.
Endoscopy Solutions excluding pulmonology
posted 33.3% organic growth, accounting for 47% of
Ambu’s total endoscopy revenue. The biggest growth
drivers were urology and ENT, which posted continued
high double-digit growth.
DRIVERS OF THE QUARTER
Pulmonology posted 13.9% organic for Q2, account-
ing for 53% of the total endoscopy revenue. Ambu’s
bronchoscopy portfolio was the biggest growth contri-
butor, while also VivaSight™ 2 DLT contributed positi-
vely, due to the global market re-launch in March 2023.
The new generation aScope™ Duodeno 2 constitutes
a step change from previous generations, driven by
valuable collaboration with healthcare professionals
and aimed to meet the unique needs of gastroentero-
logists performing ERCP procedures. Ambu will
conduct an extended controlled market release with
key hospitals to evaluate the clinical performance in a
real-life setting. The solution will be available in the
market from 2024/25, and European clearance is
expected to be obtained later in 2024. Globally, the
solution targets 0.4 million annual procedures.
Ear-nose-throat (ENT) and urology continued their
double-digit organic growth trajectory, due to an
increased pace of order uptakes and penetration of
new customers, especially in North America and
Europe. Otolaryngologists and urologists value the
workflow efficiencies brought forth by Ambu’s single-
use solutions, which supports the continued con-
version towards single-use in the two segments.
Moreover, the strong growth in pulmonology was
positively impacted by the flu season this quarter,
which overall reached a level above a five-year average.
It was also slightly positively impacted by post-Covid-
19 market normalisation, with health systems having
more balanced order patterns.
Gastroenterology (GI) sales continued growing and
were mainly driven by Ambu’s two gastroscope solu-
tions, aScope™ Gastro and aScope™ Gastro Large.
The GI segment accounts for a small part of Ambu’s
Endoscopy Solutions business, representing a long-
term growth potential for Ambu. Focus is on applying
a stepwise expansion within high-need, niche areas
and bringing new functionalities to customers by
leveraging new technology, fuelling long-term growth.
The Center for Medicare & Medicaid Services (CMS)
granted the aScope 5 Broncho HD TPT effective 1
January 2024, enabling incremental reimbursement
payments for outpatient procedures performed with
Ambu’s fifth-generation bronchoscope. TPT was
granted due to the solution’s substantial clinical
improvement, compared to existing single-use and
reusable bronchoscopy technologies. Ambu has
received positive interest towards this opportunity.
Endoscopy Solutions
organic revenue growth
22.3%
In Q2, Ambu strengthened its gastroenterology (GI)
offering by obtaining North American regulatory
clearance of two new solutions, the aScope™ Gastro
in Q2 2023/24
The aScope™ 5 Broncho HD targets the bronchoscopy
suite, representing a new customer group for Ambu.
6
Company announcement no. 11 2023/24
|
14 May 2024
